- call +1-201-465-4211
- email sales@mrinsights.biz
Scope of the Report:
The global Long-Acting Injectable Antipsychotics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Long-Acting Injectable Antipsychotics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Long-Acting Injectable Antipsychotics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Long-Acting Injectable Antipsychotics market by product type and applications/end industries.
Market Segment by Companies, this report covers
Eli Lilly
Pfizer
GlaxoSmithKline
Johnson & Johnson
Lupin Limited
Zogenix
DURECT
Medincel
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Small and Middle Sized Molecule
Large Sized Molecule
Market Segment by Applications, can be divided into
Schizophrenia
Other Psychotic Disorders
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Long-Acting Injectable Antipsychotics Market Overview
1.1 Product Overview and Scope of Long-Acting Injectable Antipsychotics
1.2 Classification of Long-Acting Injectable Antipsychotics by Types
1.2.1 Global Long-Acting Injectable Antipsychotics Revenue Comparison by Types (2017-2023)
1.2.2 Global Long-Acting Injectable Antipsychotics Revenue Market Share by Types in 2017
1.2.3 Small and Middle Sized Molecule
1.2.4 Large Sized Molecule
1.3 Global Long-Acting Injectable Antipsychotics Market by Application
1.3.1 Global Long-Acting Injectable Antipsychotics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Schizophrenia
1.3.3 Other Psychotic Disorders
1.4 Global Long-Acting Injectable Antipsychotics Market by Regions
1.4.1 Global Long-Acting Injectable Antipsychotics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Long-Acting Injectable Antipsychotics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Long-Acting Injectable Antipsychotics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Long-Acting Injectable Antipsychotics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Long-Acting Injectable Antipsychotics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Long-Acting Injectable Antipsychotics Status and Prospect (2013-2023)
1.5 Global Market Size of Long-Acting Injectable Antipsychotics (2013-2023)
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Business Overview
2.1.2 Long-Acting Injectable Antipsychotics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Eli Lilly Long-Acting Injectable Antipsychotics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Pfizer
2.2.1 Business Overview
2.2.2 Long-Acting Injectable Antipsychotics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Pfizer Long-Acting Injectable Antipsychotics Revenue, Gross Margin and Market Share (2016-2017)
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.2 Long-Acting Injectable Antipsychotics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GlaxoSmithKline Long-Acting Injectable Antipsychotics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Johnson & Johnson
2.4.1 Business Overview
2.4.2 Long-Acting Injectable Antipsychotics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Johnson & Johnson Long-Acting Injectable Antipsychotics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Lupin Limited
2.5.1 Business Overview
2.5.2 Long-Acting Injectable Antipsychotics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Lupin Limited Long-Acting Injectable Antipsychotics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Zogenix
2.6.1 Business Overview
2.6.2 Long-Acting Injectable Antipsychotics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Zogenix Long-Acting Injectable Antipsychotics Revenue, Gross Margin and Market Share (2016-2017)
2.7 DURECT
2.7.1 Business Overview
2.7.2 Long-Acting Injectable Antipsychotics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 DURECT Long-Acting Injectable Antipsychotics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Medincel
2.8.1 Business Overview
2.8.2 Long-Acting Injectable Antipsychotics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Medincel Long-Acting Injectable Antipsychotics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Long-Acting Injectable Antipsychotics Market Competition, by Players
3.1 Global Long-Acting Injectable Antipsychotics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Long-Acting Injectable Antipsychotics Players Market Share
3.2.2 Top 10 Long-Acting Injectable Antipsychotics Players Market Share
3.3 Market Competition Trend
4 Global Long-Acting Injectable Antipsychotics Market Size by Regions
4.1 Global Long-Acting Injectable Antipsychotics Revenue and Market Share by Regions
4.2 North America Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
4.3 Europe Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
4.5 South America Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
5 North America Long-Acting Injectable Antipsychotics Revenue by Countries
5.1 North America Long-Acting Injectable Antipsychotics Revenue by Countries (2013-2018)
5.2 USA Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
5.3 Canada Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
5.4 Mexico Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
6 Europe Long-Acting Injectable Antipsychotics Revenue by Countries
6.1 Europe Long-Acting Injectable Antipsychotics Revenue by Countries (2013-2018)
6.2 Germany Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
6.3 UK Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
6.4 France Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
6.5 Russia Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
6.6 Italy Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Long-Acting Injectable Antipsychotics Revenue by Countries
7.1 Asia-Pacific Long-Acting Injectable Antipsychotics Revenue by Countries (2013-2018)
7.2 China Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
7.3 Japan Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
7.4 Korea Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
7.5 India Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
8 South America Long-Acting Injectable Antipsychotics Revenue by Countries
8.1 South America Long-Acting Injectable Antipsychotics Revenue by Countries (2013-2018)
8.2 Brazil Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
8.3 Argentina Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
8.4 Colombia Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Long-Acting Injectable Antipsychotics by Countries
9.1 Middle East and Africa Long-Acting Injectable Antipsychotics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
9.3 UAE Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
9.4 Egypt Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
9.6 South Africa Long-Acting Injectable Antipsychotics Revenue and Growth Rate (2013-2018)
10 Global Long-Acting Injectable Antipsychotics Market Segment by Type
10.1 Global Long-Acting Injectable Antipsychotics Revenue and Market Share by Type (2013-2018)
10.2 Global Long-Acting Injectable Antipsychotics Market Forecast by Type (2018-2023)
10.3 Small and Middle Sized Molecule Revenue Growth Rate (2013-2023)
10.4 Large Sized Molecule Revenue Growth Rate (2013-2023)
11 Global Long-Acting Injectable Antipsychotics Market Segment by Application
11.1 Global Long-Acting Injectable Antipsychotics Revenue Market Share by Application (2013-2018)
11.2 Long-Acting Injectable Antipsychotics Market Forecast by Application (2018-2023)
11.3 Schizophrenia Revenue Growth (2013-2018)
11.4 Other Psychotic Disorders Revenue Growth (2013-2018)
12 Global Long-Acting Injectable Antipsychotics Market Size Forecast (2018-2023)
12.1 Global Long-Acting Injectable Antipsychotics Market Size Forecast (2018-2023)
12.2 Global Long-Acting Injectable Antipsychotics Market Forecast by Regions (2018-2023)
12.3 North America Long-Acting Injectable Antipsychotics Revenue Market Forecast (2018-2023)
12.4 Europe Long-Acting Injectable Antipsychotics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Long-Acting Injectable Antipsychotics Revenue Market Forecast (2018-2023)
12.6 South America Long-Acting Injectable Antipsychotics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Long-Acting Injectable Antipsychotics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Long-Acting Injectable Antipsychotics Picture
Table Product Specifications of Long-Acting Injectable Antipsychotics
Table Global Long-Acting Injectable Antipsychotic
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
